Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO
08 Feb 2023
Executive Change
Eurobio Scientific formalises the appointment of Anne-Sophie Hérelle as Group CFO
EUROBIO SCIENTIFIC FORMALISES THE APPOINTMENT
OF ANNE-SOPHIE HERELLE AS GROUP CFO
Paris, February 8, 2023 – 5:45 pm
Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, formalises the appointment of Anne-Sophie Hérelle as Group Chief Financial Officer.
Anne-Sophie Hérelle joined the company as Group CFO in October 2022, in charge of finance, investor relations and information systems. She is a member of the Group Executive Committee and the CSR Committee.
Anne-Sophie has over 20 years of experience in Finance.
She started her career with JPMorgan in London as an M&A advisor for industrial clients throughout Europe before joining the French Sovereign Fund (Fonds Stratégique d’Investissement – FSI, now Bpifrance Investment) as an Investment Director when it was created in 2009. She was promoted Director and member of Bpifrance Capital Development’s Executive Committee in 2017, in charge for investments in mid and large caps. She served as a director representing Bpifrance with several French companies in various industries, notably Nexans, Cerba Healthcare, CMA CGM, Total Eren, Galileo Global Education, PointVision, Medipole, Cegedim, Novasep, NGE, Quadran,...
Anne-Sophie Hérelle graduated from HEC Paris.
Next financial meetings
2022 results: April 5, 2023, after market closes
Annual shareholders’ meeting : June 12, 2023
Half-year 2023 sales : July 24, 2023, after market closes
Half-year results : October 11, 2023, after market closes
About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 250 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium and Utrecht in The Netherlands.
Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM.
For more information, please visit: www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP
Attachment
230208PR_Eurobio Scientific_nominCFO_EN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.